- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.03. | H.C. Wainwright raises Tourmaline Bio stock target to $50 | 3 | Investing.com | ||
| 13.03. | Tourmaline Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 13.03. | Talaris Therapeutics GAAP EPS of -$0.86 | 3 | Seeking Alpha | ||
| 13.03. | Tourmaline Bio, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 13.03. | Tourmaline Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.03. | Tourmaline Bio, Inc.: Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 121 | GlobeNewswire (Europe) | - Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total participants, on track to report topline data in the... ► Artikel lesen | |
| 06.03. | Tourmaline Bio rises as Wedbush initiates with Outperform | 2 | Seeking Alpha | ||
| 06.03. | This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday | 1 | Benzinga.com | ||
| TOURMALINE BIO Aktie jetzt für 0€ handeln | |||||
| 27.02. | Truist maintains $74 target on Tourmaline Bio stock, reiterates buy | 3 | Investing.com | ||
| 17.01. | Short Interest in Tourmaline Bio, Inc. (NASDAQ:TRML) Rises By 26.8% | 3 | MarketBeat | ||
| 10.01. | Tourmaline Bio, Inc.: Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker | 1 | GlobeNewswire (USA) | ||
| 10.12.24 | Tourmaline Bio erweitert klinische Studie und Beirat | 2 | Investing.com Deutsch | ||
| 10.12.24 | Tourmaline Bio expands trial and advisory board | 1 | Investing.com | ||
| 10.12.24 | Tourmaline Bio, Inc.: Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day | 164 | GlobeNewswire (Europe) | - Phase 2 TRANQUILITY trial surpasses enrollment target, with 143 total patients enrolled; topline data expected in second quarter of 2025 - - Deepak L. Bhatt, MD, MPH, MBA and Dipender Gill, MD,... ► Artikel lesen | |
| 10.12.24 | Tourmaline Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.11.24 | Tourmaline Bio, Inc.: Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024 | 3 | GlobeNewswire (USA) | ||
| 07.11.24 | Tourmaline Bio files for $350M mixed securities shelf | 1 | Seeking Alpha | ||
| 07.11.24 | Tourmaline Bio, Inc.: Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights | 150 | GlobeNewswire (Europe) | - On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 - - Assembled Cardiovascular Scientific Advisory Board (CV SAB), comprised of leading academic and industry... ► Artikel lesen | |
| 07.11.24 | Tourmaline Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11.24 | Tourmaline Bio, Inc. - 8-K, Current Report | - | SEC Filings |
Seite:
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 86,90 | -1,36 % | Übernahmespekulationen und Kaufempfehlungen: Bayer, BioNTech, Evotec, BioNxt Solutions Aktie | Während bei Evotec derzeit die Übernahmespekulationen pausieren, nehmen sie bei BioNxt Solutions Fahrt auf. Das Unternehmen will in den kommenden 60 Tagen wichtige Meilensteine auf dem Weg zur Vermarktung... ► Artikel lesen | |
| EVOTEC | 6,000 | -1,23 % | Deutz, Evotec, HelloFresh, Hensoldt, K+S, Verbio u.a. - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| CUREVAC | 2,788 | +0,50 % | EQS-News: CureVac erhält positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im Rechtsstreit mit BioNTech SE | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Patent
CureVac erhält positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im Rechtsstreit mit BioNTech SE
27.03.2025... ► Artikel lesen | |
| NOVAVAX | 6,433 | -0,66 % | Moderna, Novavax Shares Are Sliding Wednesday: What's Going On? | ||
| INFLARX | 1,110 | +1,37 % | Guggenheim Raises InflaRx (NASDAQ:IFRX) Price Target to $10.00 | ||
| CSL | 143,80 | +0,38 % | CSL shares haven't been this cheap in 9 years: Time to buy? | ||
| COHERUS | 0,788 | +1,23 % | Coherus BioSciences, Inc.: Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting | ||
| OCULAR THERAPEUTIX | 7,376 | +5,55 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | BEDFORD, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, today announced that... ► Artikel lesen | |
| CHIMERIX | 7,820 | +0,26 % | Chimerix Inc. (NASDAQ:CMRX) Amazing Performance So Far In 2025 | ||
| CYTOMX THERAPEUTICS | 0,570 | -1,81 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update | - Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase 1a clinical data to be presented in 1H 2025 - - CX-801... ► Artikel lesen | |
| ORUKA THERAPEUTICS | 11,200 | -3,45 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting | Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year Equivalent potency to bimekizumab... ► Artikel lesen | |
| SPERO THERAPEUTICS | 0,718 | -2,45 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update | Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025Company expects to complete analysis... ► Artikel lesen | |
| CIDARA THERAPEUTICS | 20,800 | 0,00 % | Cidara Therapeutics, Inc.: Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results | Completed enrollment of 5,000 subject Phase 2b NAVIGATE trialSevere flu season enables potential mid-year assessment of efficacyClosed $105.0 million financing with new and existing investorsSignificantly... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 25,400 | -0,78 % | Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Analysts at Jones Trading | ||
| NEXTCURE | 0,520 | +14,92 % | NextCure Provides Business Update and Reports Full Year 2024 Financial Results | Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plan to initiate backfill cohorts in the second half of 2025Cash of approximately $68.6 million... ► Artikel lesen |
Das Unternehmen TOURMALINE BIO INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 16,730 Euro. Die Dividendendrendite beträgt aktuell 0,00 % (berechnet anhand der Ausschüttung von 0,00 Euro in den letzten 12 Monaten).
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TOURMALINE BIO INC finden Sie auf Wallstreet Online.
